Rhythm Pharmaceuticals, Inc. (RYTM)

38.11 -0.34 (-0.88%) At close: 04:00PM EDT

Rhythm Pharmaceuticals, Inc.

222 Berkeley Street
12th Floor
Boston, MA 02116
United States
857 264 4280
https://rhythmtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 226

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David P. Meeker M.D.	Chairman, President & CEO	1.17M	N/A	1954
Mr. Hunter C. Smith M.B.A.	CFO & Treasurer	692.2k	N/A	1969
Mr. Joseph Shulman	Chief Technical Officer	608.2k	N/A	1975
Mr. Yann Mazabraud	Executive VP & Head of International	747.43k	N/A	1973
Ms. Jennifer Lee	Executive VP & Head of North America	644.2k	N/A	1976
Mr. Christopher German	Corporate Controller, Principal Accounting Officer & Executive Director	N/A	N/A	1971
Mr. David Connolly	Head of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Jim Flaherty	Senior VP & General Counsel	N/A	N/A	N/A
Ms. Sarah Ryan	Vice President of Sales & Marketing	N/A	N/A	N/A
Ms. Pamela J. Cramer	Chief Human Resources Officer	N/A	N/A	1974

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Corporate governance

Rhythm Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.